TrialBreast cancer (Tokyo, Japan)2023

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.

Hideko Yamauchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.